• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021

    11/1/21 7:00:00 AM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVEO alert in real time by email

    AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 8, 2021, to discuss the financial results and provide a business update.

    The call can be accessed by dialing (844) 882-7841 (U.S. and Canada) or (574) 990-9828 (international). The passcode for the conference call is 1647457. To access the live webcast, or the subsequent archived recording, please visit the Calendar of Events sub-section within the Investors section of the AVEO website at www.aveooncology.com.

    About AVEO Pharmaceuticals, Inc.

    AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled "Risk Factor Summary" and "Risk Factors" in AVEO's most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO's views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO's views as of any date other than the date of this press release.

    Any reference to AVEO's website address in this press release is intended to be an inactive textual reference only and not an active hyperlink.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005200/en/

    Get the next $AVEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVEO

    DatePrice TargetRatingAnalyst
    11/8/2022$15.00Buy → Hold
    Stifel
    7/12/2021$27.00 → $19.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AVEO
    Financials

    Live finance-specific insights

    See more
    • AVEO Oncology Reports Third Quarter 2022 Financial Results

      – Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis – BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights At September 30, 2022, AVEO r

      11/7/22 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash

      Acquisition Provides LG Chem's Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem's Efforts to Deliver Continued Growth AVEO Will Have Enhanced Ability to Deliver on its Mission to Improve the Lives of Patients with CancerAVEO to Establish and Operate as the U.S. Commercial Foundation for LG Chem Life Sciences' Oncology SegmentTransaction Price Represents a 43% Premium to AVEO's Closing Price on October 17, 2022 SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) and AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercia

      10/18/22 4:30:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Reports Second Quarter 2022 Financial Results

      – Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100.0 million to $110.0 million – – Company Streamlines Planned R&D Spending and Lowers Guidance to $50.0 million from $60.0 million to $70.0 million – – Company to host conference call today at 4:30 p.m. ET – BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better

      8/4/22 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVEO Oncology downgraded by Stifel with a new price target

      Stifel downgraded AVEO Oncology from Buy to Hold and set a new price target of $15.00

      11/8/22 6:15:04 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on AVEO Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of AVEO Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $27.00 previously

      7/12/21 6:05:44 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on AVEO Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of AVEO Pharmaceuticals with a rating of Outperform and set a new price target of $18.00 from $10.00 previously

      3/11/21 6:30:25 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FOTIVDA issued to AVEO PHARMACEUTICALS INC

      Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

      3/29/21 5:44:34 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FOTIVDA

      Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

      3/10/21 2:49:22 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Leadership Updates

    Live Leadership Updates

    See more
    • AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer

      - Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience - AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company's organizational efficiency and advancing its pipeline of products. "We are excited to welcome Jeb to the team during an important phase of AVEO's evolution as an integrated clinical development and commercial organization," said Michael Bailey, president and chief executive officer of AVEO. "With a successful

      12/1/21 7:00:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors

      AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company's Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director of the Program in Oncology at the University of Maryland School of Medicine. He also serves as director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. "Dr. Cullen, among the leading voices in cancer research and treatment, has made many important contributions to the evolving tre

      4/16/21 7:00:00 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update

      BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration’s (FDA) recent approval of FOTIVDA marks a transformative event for AVEO, and we are eager to demonstrate FOTIVDA’s potential to serve as a meaningful new treatment option within the growing relapsed or refractory advanced renal cell carcinoma (RCC) patient population. We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month,” said Michael Bailey, president and chief executive officer of AVEO. “In parallel, we remain focused on the evalua

      3/16/21 4:05:00 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

      The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors. The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI. Keynote speakers include: Steve Kraus, Partner at Bessemer Venture Partners and world-renown

      3/22/24 6:14:00 PM ET
      $BEAM
      $DASH
      $LYFT
      $AVEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Consumer Discretionary
    • LG Chem Completes Acquisition of AVEO Oncology

      SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a fully diluted basis. "We are excited to complete LG Chem's acquisition of AVEO, which will position us to deliver on our mission of becoming one of the world's leading oncology companies with a robust clinical pipeline of innovative therapies," said Shin Hak-Cheol, Chief Execu

      1/19/23 4:35:03 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AVEO Oncology Stockholders Approve Acquisition by LG Chem

      BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the "Special Meeting") held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement"). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction. "Today's approval is a significant step toward the c

      1/5/23 7:35:35 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bate Kenneth returned $5,625 worth of shares to the company (375 units at $15.00), decreasing direct ownership by 50% to 375 units (tax liability)

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:19:11 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Evnin Anthony B returned $627,615 worth of shares to the company (41,841 units at $15.00), closing all direct ownership in the company to satisfy tax liability

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:16:18 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ledell Jebediah (tax withholding)

      4 - AVEO PHARMACEUTICALS, INC. (0001325879) (Issuer)

      1/19/23 5:16:10 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13D/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      11/1/22 5:01:48 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      10/20/22 4:05:20 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AVEO Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AVEO PHARMACEUTICALS, INC. (0001325879) (Subject)

      2/11/22 3:32:10 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVEO
    SEC Filings

    See more
    • SEC Form 15-12G filed by AVEO Pharmaceuticals Inc.

      15-12G - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/30/23 4:07:52 PM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.

      EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/24/23 12:15:15 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.

      EFFECT - AVEO PHARMACEUTICALS, INC. (0001325879) (Filer)

      1/24/23 12:15:19 AM ET
      $AVEO
      Biotechnology: Pharmaceutical Preparations
      Health Care